

## Supplementary

**Table S1** Characterization of patients receiving induction chemotherapy by chemotherapy regimen and participation in a clinical trial

Characteristics	TMT, n (%)	BMT, n (%)
Chemotherapy regimen		
Carboplatin and paclitaxel	5 (56)	3 (75)
FOLFOX	1 (11)	0 (0)
Cisplatin and irinotecan	1 (11)	0 (0)
Multiple, per research protocol	2 (22)	0 (0)
Other	0 (0)	1 (25)
On research protocol		
No	1 (11)	0 (0)
Yes	8 (89)	4 (100)

**Table S2** Chemotherapy agents utilized in patients receiving BMT and TMT

Chemotherapy regimen	TMT, n (%)	BMT, n (%)
Carboplatin and paclitaxel	37 (73)	34 (77)
Cisplatin and paclitaxel	0 (0)	3 (7)
FOLFOX	1 (2)	0 (0)
Cisplatin and 5-fluorouracil	3 (6)	0 (0)
Cisplatin and irinotecan	4 (8)	1 (2)
Multiple, per research protocol	4 (8)	0 (0)
Other	0 (0)	5 (11)
Data unavailable	2 (4)	1 (2)

**Table S3** Univariable and multivariable cox regression of overall survival

Variable	Univariable analysis			Multivariable analysis		
	HR	(95% CI)	P value	HR	(95% CI)	P value
Trimodality therapy	0.31	(0.19–0.51)	<0.001	0.37	(0.21–0.64)	<0.001
History of neoplasm	1.73	(1.01–2.97)	0.03	1.74	(0.97–3.12)	0.06
Age-adjusted CCI						
5–7	1.32	(0.73–2.36)	0.3	0.98	(0.53–1.80)	0.9
8–10	2.35	(1.11–4.96)	0.03	1.32	(0.60–2.91)	0.5
CROSS-Ineligible	1.99	(1.16–3.42)	0.01	–	–	–

Univariable and multivariable cox regression of overall survival. CROSS eligibility was excluded from multivariable regression due to collinearity with history of neoplasm. CCI, Charlson Comorbidity Index.